Correlation of heart-type fatty acid–binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk

Boscheri, Alessandra; Wunderlich, Carsten; Langer, Martin; Schoen, Steffen; Wiedemann, Bärbel; Stolte, Dirk; Elmer, Gesa; Barthel, Peggy; Strasser, Ruth H.

doi:10.1016/j.ahj.2010.05.010

Cited by 61 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, in our study patients and in the presence of NT-proBNP association was found neither with the short-term adverse events nor long-term mortality in terms of H-FABP. However, previous studies on H-FABP have suggested this marker as a promising biomarker for risk stratification in acute PE [6,15,16,18]. These conflicting findings may be to some extent due to the relatively low number of events in our study population or the different inclusion criteria for our study.…”

Section: Discussioncontrasting

confidence: 51%

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Jenab

Pourjafari

Sotoudeh

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Acute pulmonary embolism (PE) is a cardiovascular challenge with potentially fatal consequences.This study was designed to observe the association of novel cardiac biomarkers with outcome in this setting. In this prospective study, from 86 patients with a confirmed diagnosis of PE, 59 patients met the inclusion criteria (22 men, 37 women; mean age, 63.36±15.04 y). The plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), tenascin-C, and D-dimer were measured at the time of confirmed diagnosis. The endpoints of the study were defined as the short-term adverse outcome and long-term all-cause mortality.Totally, 11.8% (7/59) of the patients had the short-term adverse outcome. The mean value of logNT-proBNP was 6.40±1.66 pg/ml. Among all the examined biomarkers, only the mean value of logNT-proBNP was significantly higher in the patients with the short-term adverse outcome (7.88±0.67 vs 6.22± 1.66 pg/ml; OR, 2.359; 95% CI, 1.037 to 5.367; p=0.041). After adjustment, a threefold increase in the short-term adverse outcome was identified (OR, 3.239; 95% CI, 0.877 to 11.967; p=0.078). Overall, 18.64% (11/59) of the patients had expired by the long-term follow-up. Moreover, adjustment revealed an evidence regarding association between increased logNT-proBNP levels and longterm mortality (HR, 2.163; 95%CI, 0.910 to 5.142; p=0.081).Our study could find evidences on association between increased level of NT-proBNP and short-term adverse outcome and/or long-term mortality in PE. This biomarker may be capable of improving prediction of outcome and clinical care in non-high-risk PE.

show abstract

Section: Discussioncontrasting

confidence: 51%

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Jenab

Pourjafari

Sotoudeh

et al. 2017

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…During the past decade, strategies have mainly focused on the identification of patients with an elevated (in Europe also called intermediate) 1 risk of an early adverse outcome who might benefit from aggressive, eg, thrombolytic, treatment regimens. Laboratory markers of myocardial (right ventricular) dysfunction such as the natriuretic peptides, 19 or injury such as the cardiac troponins 4,20 or heart-type fatty acid-binding protein, [21][22][23] and imaging procedures (echocardiography, computed tomography) for assessment of size and function of the right ventricle 24 all were reported to be useful tools in this approach. Nevertheless, their therapeutic implications remain controversial to date, 3,25 in particular, because none of them was tested in a prospective management trial.…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism

et al. 2011

View full text Add to dashboard Cite

Background-The new, high-sensitivity troponin T (hsTnT) assay may improve risk stratification of normotensive patients with acute pulmonary embolism (PE). We externally validated the prognostic value of hsTnT, and of the simplified Pulmonary Embolism Severity Index (sPESI), in a large multicenter cohort. Methods and Results-We prospectively examined 526 normotensive patients with acute PE; of those, 31 (5.9%) had an adverse 30-day outcome. The predefined hsTnT cutoff value of 14 pg/mL was associated with a high prognostic sensitivity and negative predictive value, comparable to those of the sPESI. were identified as low risk by a sPESI of 0 and hsTnT Ͻ14 pg/mL; none of them had an adverse 30-day outcome. During 6-month follow-up, 52 patients (9.9%) died. Kaplan-Meier analysis illustrated that patients with hsTnT Ն14 pg/mL (Pϭ0.001) and those with sPESI Ն1 (PϽ0.001) had a decreased probability of 6-month survival. Patients with sPESI of 0 and hsTnT Ͻ14 pg/mL at baseline had a 42% reduction in the risk of dying (hazard ratio, 0.58 [0.01-0.42]; Pϭ0.005). Conclusions-The hsTnT assay and the sPESI improve risk stratification of acute PE. Combination of both modalities may yield additive prognostic information and particularly identify possible candidates for out-of-hospital treatment.

show abstract

“…Yapılan başka çalışmalarda, kısa dönem ölümleri göstermede, birçok değişken arasında sadece H-FABP'ın bağımsız bir belirleyici olduğu gösterilmiştir 64,65 . Dellas ve ark'ları, H-FABP'nın sadece 30 günlük mortaliteyi değil aynı zamanda uzun dönem prognonuzu göstermede bağımsız bir belirleyici olduğunu tespit ettiler 66 .…”

Section: Kalp Tipi Yağ Asidi Bağlayıcı Proteinunclassified

“…Dellas ve ark'ları, H-FABP'nın sadece 30 günlük mortaliteyi değil aynı zamanda uzun dönem prognonuzu göstermede bağımsız bir belirleyici olduğunu tespit ettiler 66 . Konu ile alakalı yapılan çalışmaların hemen hepsinde, H-FABP'ın oldukça yüksek NPD (%99-%100) ile PPD (%28-%71)'e sahip olduğu saptanmıştır [64][65][66][67] . Ayrıca yapılan çalışmalarda, H-FABP'ın kısa dönem prognostik etkinliğinin cTn, BNP, EKO ve BT bulgularından daha değerli olduğu gösterilmiştir 66,67 .…”

Section: Kalp Tipi Yağ Asidi Bağlayıcı Proteinunclassified

“…Ayrıca yapılan çalışmalarda, H-FABP'ın kısa dönem prognostik etkinliğinin cTn, BNP, EKO ve BT bulgularından daha değerli olduğu gösterilmiştir 66,67 . PPD'nın diğer belirteçlere göre daha yüksek olması nedeniyle, trombolitik tedavi uygulanacak hastaların seçiminde yardımcı olabileceği belirtilmektedir 63,65,66 . Sahip olduğu özellikleri nedeniyle H-FABP'ın, PE'nın prognoz değerlendirmesinde en etkili biyobelirteç olduğu kabul edilmektedir.…”

Section: Kalp Tipi Yağ Asidi Bağlayıcı Proteinunclassified

See 1 more Smart Citation

Pulmoner Embolide Şiddet ve Prognozun Değerlendirilmesi

Kılıç¹

2014

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Although technology of diagnosis and treatment continues to improve, the mortality rate of pulmonary embolism remains high. It was detected that more than 10% of the hospital mortality is related to pulmonary embolism. Really, management of this disease is hard. It is a consensus that patients with massif pulmonary embolism, which is characterized hemodynamic impairment, and have indications of aggressive treatments such as thrombolytic. But the issue of treatment of the hemodynamically stable patients with pulmonary embolism accompanied by right ventricular dysfunction is not clear. In last year, because of the cost-effectiveness, it has been reported that lowrisk patients could treated as outpatients. Hence, it is need to make an accurate judgment of pulmonary embolism severity and prognosis. Biomarkers such as brain natriuretic peptide, N-terminal probrain natriuretic peptide, cardiac troponin, and heart-type fatty acid-binding protein are very important indicators of pulmonary embolism severity and short-term prognosis. Furthermore, it was reported that the pulmonary embolism severity index and simplified pulmonary embolism severity index are more suitable assessing the overall mortality and long-term prognosis. It is suggested that they could be used especially in identifying low risk group. In this review, in the recent literature, it will be assessed biomarkers, findings right ventricular dysfunction which were detected by imaging tool, and a few clinical prognostic model for evaluating pulmonary embolism severity and prognosis. Key words: Biomarker; pulmonar mebolis; pulmonary embolism severity index; prognosis; risk evaluation ÖZET Tanı ve tedavideki teknolojik gelişmelere rağmen, pulmoner emboliye bağlı mortalite halen yüksektir. Hastane ölümlerinin %10'dan fazlası pulmoner emboli ile alakalı olduğu tespit edilmiştir. Gerçekten,

show abstract

Correlation of heart-type fatty acid–binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk

Cited by 61 publications

References 23 publications

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Comparing the effect of cardiac biomarkers on the outcome of normotensive patients with acute pulmonary embolism

Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism

Pulmoner Embolide Şiddet ve Prognozun Değerlendirilmesi

Contact Info

Product

Resources

About